Nucleus 22 Cochlear Implant System
Cochlear Americas · Decision date Sep 28, 2026
What did the FDA decide?
The FDA record for P840024/S099, dated 2026-09-28 and filed by Cochlear Americas, is a 30-day notice supplement whose stated reason is a process change involving a manufacturer, sterilizer, packager or supplier. The submitted statement describes a change to the joining process in the manufacturing of the NEUF Child Lock component in Cochlear Sound Processors, with the device category listed as cochlear implant and product code MCM.
The P840024 identifier ties this supplement to the existing PMA record rather than constituting approval of the whole Nucleus 22 Cochlear Implant System. The statement does not describe the prior joining process, the changed parameters, validation data, or whether the NEUF Child Lock component is itself a sound processor part, so the technical extent of the change remains unspecified here. The notice reports a manufacturing process adjustment; it is not independent evidence of safety or clinical effectiveness.
FDA approval order statement
a change to the joining process in the manufacturing of the NEUF Child Lock component in Cochlear Sound Processors
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ear, Nose, Throat
- Decision date
- Sep 28, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P840024/S099
- Regulatory pathway
- PMA supplement
- Applicant
- Cochlear Americas
- Product code
- MCM
- Decision code
- OK30
- Decision date
- Sep 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, cochlear.
- Applicant
- Cochlear Americas
- Product code
- MCM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P840024. Subsequent supplements may change the device or its indications.
FDA decision timeline
P840024 · Original PMA
NUCLEUS MULTICHANNEL IMPLANTABLE HEARING PROSTHESI
P840024/S099 received
Application receipt date recorded by FDA.
P840024/S099 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P840024. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P840024
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cochlear Americas | PMA approval | Oct 31, 1985 | FDA |
Explore the linked device profile
Other records with product code MCM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MED-EL Cochlear Implant SystemP000025/S136 | Med-El Corp. | PMA supplement | Oct 9, 2026 | FDA |
Nucleus 22 Cochlear Implant SystemP890027/S067 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Nucleus 24 Cochlear Implant SystemP970051/S244 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
CLARION MULTI-STRATEGY COCHLEAR IMPLANTP960058/S178 | Advanced Bionics | PMA supplement | Sep 18, 2026 | FDA |
HiResolution Bionic Ear SystemP960058/S177 | Advanced Bionics | PMA supplement | Sep 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cochlear Americas
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 10350 Park Meadows Dr., Lone Tree, CO, 80124
Sources and methodology
- Original FDA record: P840024/S099
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


